This database contains 201 studies, archived under the term: "double-blind method"
Click here to filter this large number of results.
Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial – HYVET
Peters, Ruth,
Beckett, Nigel,
Fagard, Robert,
Thijs, Lutgarde,
Wang, Ji-Guang,
Forette, Francoise,
Pereira, Lisa,
Fletcher, Astrid,
Bulpitt, Christopher
Objectives: High blood pressure (BP) has been associated with increased risk of dementia. Concerns have been raised about lowering BP too far in the very elderly and thereby increasing risk. There is some evidence to suggest a potential ‘J’-shaped relationship between DBP and risk of cognitive impairment. This was investigated using data from the HYpertension […]
The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer’s disease
Ohnishi, Takashi,
Sakiyama, Yojiro,
Okuri, Yuichi,
Kimura, Yuji,
Sugiyama, Nami,
Saito, Takayuki,
Takahashi, Masayoshi,
Kobayashi, Takumi
The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far. The present analyses aimed to identify factors for predicting long-term outcome of galantamine treatment. Analyses were conducted with data from a 24 weeks randomized, double-blind, placebo controlled trial to […]
Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer’s disease
O'Caoimh, Rónán,
Healy, Liam,
Gao, Yang,
Svendrovski, Anton,
Kerins, David M.,
Eustace, Joseph,
Kehoe, Patrick Gavin,
Guyatt, Gordon,
Molloy, D. William
Background: Centrally acting angiotensin converting enzyme inhibitors (CACE-Is) are associated with reduced rates of cognitive decline in patients with dementia. CACE-Is may also improve exercise tolerance in functionally impaired older adults with normal cognition, suggesting that CACE-Is may positively influence activities of daily living (ADL) in dementia.; Objective: To compare rates of decline in patients […]
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation
Nathan, Pradeep J.,
Boardley, Rebecca,
Scott, Nicola,
Berges, Alienor,
Maruff, Paul,
Sivananthan, Tharani,
Upton, Neil,
Lowy, Martin T.,
Nestor, Peter J.,
Lai, Robert
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H₃ receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study […]
Ingestion of Chlorella reduced the oxidation of erythrocyte membrane lipids in senior Japanese subjects
Miyazawa, Taiki,
Nakagawa, Kiyotaka,
Takekoshi, Hideo,
Higuchi, Ohki,
Kato, Shunji,
Kondo, Momoko,
Kimura, Fumiko,
Miyazawa, Teruo
Accumulation of phospholipid hydroperoxide (PLOOH) in erythrocyte membranes is an abnormality found in patients with senile dementia, including those with Alzheimer’s disease. In our previous studies, dietary xanthophylls (polar carotenoids such as lutein) were hypothesized to inhibit lipid peroxidation. In the present study, we conducted a randomized, double-blind, placebo-controlled human trial to assess the impact […]
Effect of cholinergic stimulation in early Alzheimer’s disease – functional imaging during a recognition memory task
Miettinen, Pekka S.,
Pihlajamäki, Maija,
Jauhiainen, Anne M.,
Tarkka, Ina M.,
Gröhn, Heidi,
Niskanen, Eini,
Hänninen, Tuomo,
Vanninen, Ritva,
Soininen, Hilkka
Treatment of Alzheimer’s disease (AD) with acetylcholinesterase inhibitors (AChEI) enhances cholinergic activity and alleviates clinical symptoms. In the present functional magnetic resonance imaging (fMRI) study, we investigated the effect of the AChEI rivastigmine on cognitive function and brain activation patterns during a face recognition memory task. Twenty patients with newly-diagnosed mild AD were administered a […]
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects
Mathis, Chester A.,
Kuller, Lewis H.,
Klunk, William E.,
Snitz, Beth E.,
Price, Julie C.,
Weissfeld, Lisa A.,
Rosario, Bedda L.,
Lopresti, Brian J.,
Saxton, Judith A.,
Aizenstein, Howard J.,
McDade, Eric M.,
Kamboh, M. Ilyas,
DeKosky, Steven T.,
Lopez, Oscar L.
Objective: This study examined amyloid-β (Aβ) deposition in 190 nondemented subjects aged ≥82 years to determine the proportion of Aβ-positive scans and associations with cognition, apolipoprotein E (APOE) status, brain volume, and Ginkgo biloba (Gb) treatment.; Methods: Subjects who agreed to participate had a brain magnetic resonance imaging and positron emission tomography scan with (11) […]
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington’s disease
Lundin, Anders,
Dietrichs, Espen,
Haghighi, Sara,
Göller, Marie-Louise,
Heiberg, Arvid,
Loutfi, Ghada,
Widner, Håkan,
Wiktorin, Klas,
Wiklund, Leif,
Svenningsson, Anders,
Sonesson, Clas,
Waters, Nicholas,
Waters, Susanna,
Tedroff, Joakim
Objectives: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease (HD).; Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, […]